WithdrawnPhase 2

Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients

Stopped: Low enrollment

United States0Started 2021-01-02

Plain-language summary

Single-center, open-label, pre-post treatment pilot study to evaluate the safety and effectiveness of sphenopalatine ganglia blocks for the treatment of chronic migraine in the pediatric population. 50 children with a diagnosis of chronic migraines will undergo a series of three transnasal sphenopalatine ganglia blocks to measure their effect on headache frequency, headache intensity, headache duration, and use of headache medication.

Who can participate

Age range8 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Children ages 8 to 17 years old Meet the criteria for chronic migraines Have remained stable on their current headache medication for a minimum of 4 weeks. Able to provide informed consent from parent or legal guardian Able to provide assent if subject is a minor of appropriate age Exclusion Criteria: Allergy to local anesthetic Developmental delay (e.g. non-verbal) Inability to use numeric pain scale Inability to perform or tolerate transnasal procedure Substance abuse disorders Known pregnancy

What they're measuring

Reduction in frequency of headache days: pre-treatment

Timeframe: Up to 4 weeks following consent

Reduction in frequency of headache days: post-treatment

Timeframe: Up to one year following consent

Trial details

NCT IDNCT04466826

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-02-05

View on ClinicalTrials.gov More Migraine in Children trials